Personalis, Inc. (PSNL)
Healthcare · NGM · US
Fundamentals
Valuation and ratings
Personalis, Inc. trades at USD15.39, which is 60% above the USD6.23 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 16 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
About Personalis, Inc.
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
PSNL passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
6 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Cathie Wood, ARK Investment Management LLC$50.60M · 0.4% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$2.67M · 0.0% of book
- Paul Tudor Jones, TUDOR INVESTMENT CORP ET AL$1.34M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$577.8K · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$111.0K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is Personalis, Inc. (PSNL) undervalued?
Against our discounted cash flow estimate of USD6.23, PSNL at USD15.39 is 60% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
Which funds own PSNL?
6 of the institutions we track reported a position in PSNL in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
The full research page for PSNL, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.